Press Releases

Press Contact

Press Releases

Tuebingen, Germany and Houston, Texas, September 29, 2020 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, announced today that Arnd Christ will join its leadership team as
Sep 29, 2020
Immatics today announced the completion of its business combination with Arya Sciences Acquisition Corp., a special purpose acquisition company (SPAC) sponsored by Perceptive Advisors.  Immatics N.V. will commence trading its shares under the symbol “IMTX” and its warrants under the symbol “IMTXW” on the Nasdaq Capital Market today.
Jul 02, 2020